Journal of Clinical Endocrinology & Metabolism, Vol 72, 382-386, Copyright © 1991 by Endocrine Society

ARTICLES

The course of biochemical parameters of bone turnover during treatment with corticosteroids

MF Prummel, WM Wiersinga, P Lips, GT Sanders and HP Sauerwein
Department of Endocrinology, University of Amsterdam, The Netherlands.

The mechanisms by which glucocorticoids cause osteopenia are incompletely understood. It is generally accepted that bone formation is depressed during corticosteroid treatment, but the cause of the ongoing bone resorption is less clear. Secondary hyperparathyroidism and changes in vitamin D metabolism are thought to play a role. This is based mostly on data from cross-sectional studies in heterogeneous patient groups. We, therefore, studied longitudinally the course of biochemical parameters and the hormones influencing bone turnover in a homogeneous group of 10 euthyroid patients with Graves' ophthalmopathy, all euthyroid for at least 1 yr before, during, and after a 12-week course of prednisone. Bone formation was depressed as reflected by a fall in serum osteocalcin (3.0 +/- 2.1, 1.7 +/- 1.1, and 2.4 +/- 1.9 micrograms/L at weeks 0, 4, and 12, respectively; P = 0.02) and in total alkaline phosphatase (1.15 +/- 0.33, 0.83 +/- 0.22, and 0.88 +/- 0.40 mukat/L; P = 0.001). Parameters of bone resorption (urinary hydroxyproline/creatinine ratio, serum acid phosphatase) and the levels of vitamin D metabolites remained unchanged. Serum intact PTH seemed to decrease slightly. Our findings suggest that glucocorticoid induced osteopenia is caused by a depressed bone formation in the presence of an unaltered but ongoing bone resorption. Secondary hyperparathyroidism and changes in vitamin D metabolism are apparently not involved.

This article has been cited by other articles:

				K. E. Scholz-Ahrens, G. Delling, B. Stampa, A. Helfenstein, H.-J. Hahne, Y. Acil, W. Timm, R. Barkmann, J. Hassenpflug, J. Schrezenmeir, et al. Glucocorticosteroid-induced osteoporosis in adult primiparous Gottingen miniature pigs: effects on bone mineral and mineral metabolism Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E385 - E395. [Abstract] [Full Text] [PDF]

				A. Dovio, L. Perazzolo, L. Saba, A. Termine, M. Capobianco, A. Bertolotto, and A. Angeli High-dose glucocorticoids increase serum levels of soluble IL-6 receptor {alpha} and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur. J. Endocrinol., May 1, 2006; 154(5): 745 - 751. [Abstract] [Full Text] [PDF]

				A. Dovio, L. Perazzolo, G. Osella, M. Ventura, A. Termine, E. Milano, A. Bertolotto, and A. Angeli Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4923 - 4928. [Abstract] [Full Text] [PDF]

				M. S. Cooper, A. Blumsohn, P. E. Goddard, W. A. Bartlett, C. H. Shackleton, R. Eastell, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3874 - 3877. [Abstract] [Full Text] [PDF]

				S. S. Yeap and D. J. Hosking Management of corticosteroid-induced osteoporosis Rheumatology, October 1, 2002; 41(10): 1088 - 1094. [Abstract] [Full Text] [PDF]

				B Gudbjornsson, U I Juliusson, and F V Gudjonsson Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice Ann Rheum Dis, January 1, 2002; 61(1): 32 - 36. [Abstract] [Full Text] [PDF]

				A. Spira, C. Gutierrez, C. Chaparro, M. A. Hutcheon, and C. K.N. Chan Osteoporosis and Lung Transplantation: A Prospective Study Chest, February 1, 2000; 117(2): 476 - 481. [Abstract] [Full Text] [PDF]

				E. Stacey, P. Korkia, M. V. J. Hukkanen, J. M. Polak, and O. M. Rutherford Decreased Nitric Oxide Levels and Bone Turnover in Amenorrheic Athletes with Spinal Osteopenia J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3056 - 3061. [Abstract] [Full Text]

				I. R. Reid Glucocorticoid Effects on Bone J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1860 - 1862. [Full Text]

				I. Chiodini, V. Carnevale, M. Torlontano, S. Fusilli, G. Guglielmi, M. Pileri, S. Modoni, A. Di Giorgio, A. Liuzzi, S. Minisola, et al. Alterations of Bone Turnover and Bone Mass at Different Skeletal Sites due to Pure Glucocorticoid Excess: Study in Eumenorrheic Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1863 - 1867. [Abstract] [Full Text]

				C. Roux, P. Oriente, R. Laan, R. A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J. M. Pouillès, S. Horlait, and B. Cortet Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1128 - 1133. [Abstract] [Full Text]

				G. Pearce, D. A. Tabensky, P. D. Delmas, H. W. G. Baker, and E. Seeman Corticosteroid-Induced Bone Loss in Men J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 801 - 806. [Abstract] [Full Text]

				G. Osella, M. Terzolo, G. Reimondo, A. Piovesan, A. Pia, A. Termine, P. Paccotti, and A. Angeli Serum Markers of Bone and Collagen Turnover in Patients with Cushing's Syndrome and in Subjects with Adrenal Incidentalomas J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3303 - 3307. [Abstract] [Full Text] [PDF]

				E. Shane, M. Rivas, D. J. McMahon, R. B. Staron, S. J. Silverberg, M. J. Seibel, D. Mancini, R. E. Michler, K. Aaronson, V. Addesso, et al. Bone Loss and Turnover after Cardiac Transplantation J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1497 - 1506. [Abstract] [Full Text] [PDF]